Conavi Medical Corp. reports developments tied to its commercial-stage medical device business in cardiovascular imaging. The company designs, manufactures and markets technologies used to guide minimally invasive cardiovascular procedures, including a next-generation hybrid intravascular imaging system that combines intravascular ultrasound and optical coherence tomography in a single platform.
Recurring news themes include FDA 510(k) clearance, U.S. commercialization preparation, clinical and academic publications on hybrid IVUS-OCT imaging, operational and financial results, equity financing, non-dilutive funding agreements, leadership changes, investor conference participation and healthcare technology recognition.
Conavi Medical (CNVIF) completed its first U.S. commercial placement and clinical cases with its FDA-cleared OCTIV hybrid coronary imaging system. The first site is NewYork-Presbyterian/Columbia University Irving Medical Center, where Dr. Megha Prasad performed the initial cases.
The placement advances the targeted U.S. rollout following FDA 510(k) clearance. OCTIV combines intravascular ultrasound and optical coherence tomography, two imaging methods, in one catheter to guide coronary interventions. Conavi introduced OCTIV as the system’s commercial name, powered by Novasight technology. The company plans to support clinical use at the hospital and advance placements at additional U.S. institutions.
Conavi Medical (CNVIF) will showcase its FDA-cleared hybrid imaging system at TCT 2026, taking place October 31–November 3 in San Diego. This is its first TCT conference since receiving FDA 510(k) clearance for the next-generation system, which combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
Dr. Megha Prasad will present a case involving hybrid imaging in complex coronary intervention and a preclinical abstract on saline-based, contrast-free imaging in a porcine model on November 2. Conavi will also participate in two CRF Imaging Lab education sessions on November 3.
Conavi Medical (CNVIF) reported a new peer-reviewed case report demonstrating how its hybrid intravascular ultrasound–optical coherence tomography (IVUS-OCT) imaging guided post-stent management in a complex coronary intervention.
The Catheterization and Cardiovascular Interventions report describes use of Conavi’s hybrid system in a 66-year-old patient after right coronary artery stenting, where combined IVUS-OCT identified proximal and distal edge dissections and white thrombus. IVUS aided vessel sizing and plaque assessment, while OCT’s higher resolution characterized dissection extent and depth and helped distinguish white thrombus from calcified nodule. The authors noted that detecting thrombus and dissections with hybrid imaging may help prevent acute vessel closure, major adverse cardiovascular events and target revascularization. Conavi also announced that Chief Technology Officer and co‑founder Amandeep Thind will lead research and development as Vice President of R&D Sumeet Dham departs.
Conavi Medical (OTCQB: CNVIF) reported Fiscal Q3 2026 net loss of $6.3 million, widening from $3.6 million a year earlier, as operating expenses rose to $6.5 million driven by higher R&D spending of $4.4 million for Novasight 3.0 and transfer-to-production activities. Fiscal Q3 licensing and R&D services revenue was $0.1 million, unchanged year over year, while revenue for the nine months ended June 30, 2026 fell to $0.5 million from $8.8 million due to non-recurring milestone revenue in the prior year. Cash and cash equivalents were $0.9 million at June 30, 2026, before closing a $10 million public offering on August 12, 2026. During the quarter Conavi received a $1.25 million milestone payment under Ontario’s Life Sciences Scale-Up Fund and achieved FDA 510(k) clearance for its next-generation Novasight Hybrid IVUS-OCT intravascular imaging system, supporting planned U.S. commercialization in H2 2026.
Conavi Medical (OTCQB: CNVIF) announced a JSCAI case report demonstrating the clinical utility of its hybrid IVUS-OCT imaging system in a complex coronary procedure for a patient with impaired renal function.
The publication describes how combining IVUS and OCT supported lesion assessment, treatment planning, stent optimization, and contrast-sparing management.
Conavi Medical (OTCQB:CNVIF) received a $1.25 million milestone payment from Ontario’s Life Sciences Scale-Up Fund after achieving U.S. FDA 510(k) clearance for its hybrid IVUS-OCT imaging system.
This brings total funding under the program to $1.75 million, with eligibility for up to $2.5 million to support commercialization, U.S. market expansion, and manufacturing scale-up.
Conavi Medical (OTCQB:CNVIF) reported Fiscal Q2 2026 results and major operational milestones for the quarter ended March 31, 2026.
Key points include FDA 510(k) clearance for its next‑generation hybrid IVUS-OCT imaging system, multiple 2026 industry awards, stable quarterly revenue, lower operating expenses, and a wider quarterly net loss.
Conavi Medical (OTCQB: CNVIF) received a 2026 TAG Innovation Award after securing FDA 510(k) clearance for its next‑generation hybrid intravascular imaging system. The platform combines IVUS and OCT in one workflow and positions the company to begin U.S. commercialization and broaden clinical adoption.
Conavi Medical (OTCQB:CNVIF) received FDA 510(k) clearance for its next-generation hybrid IVUS‑OCT intravascular imaging system on April 20, 2026. The device co-registers IVUS and OCT in a single workflow and positions Conavi for a limited U.S. commercial launch expected in H2 2026.
The company cites a >$4 billion global coronary intravascular imaging market with current IVUS/OCT penetration of 30–40%, and highlights streamlined workflow, lesion and stent analysis tools, and enhanced catheter deliverability as commercial features.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) announced that CEO Thomas Looby will present and hold one-on-one meetings at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026 in Toronto.
The CEO presentation is scheduled for April 22, 2026 at 9:30 a.m. ET at the Metro Toronto Convention Centre, with a live webcast and replay available via the company investor relations site for 30 days.